<DOC>
	<DOCNO>NCT02605434</DOCNO>
	<brief_summary>The purpose study determine whether gastric retentive Accordion Pill™ Carbidopa/Levodopa ( AP-CD/LD ) effective commercially available immediate release Carbidopa/Levodopa reduce motor fluctuation `` time '' advance Parkinson 's Disease patient .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Gastric-retentive AP-CD/LD Advanced Parkinson 's Patients</brief_title>
	<detailed_description>A multi-center , global , randomized , double-blind , double-dummy , active-controlled , parallel-group study adult subject fluctuate PD . The study 2 open label Titration period 6 week prior double blind Maintenance period . In open label period patient stabilize active comparator Sinemet® AP-CD/LD . The double blind Maintenance period 13 week long .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Main 1 . Men woman 30 85 year age , inclusive , initial screen assessment . 2 . Diagnosed Parkinson 's disease consistent UK brain bank criterion 3 . Has good response levodopa take least 4 dos IR Carbidopa/levodopa contain medication per day ( 3 doses/day Rytary ) 4 . Other AntiPD treatment ( dopamine agonist , selective MAOB inhibitor , anticholinergic agent amantadine ) permit stable least 28 day prior study entry provide anticipate changed course study 5 . Total LD daily dose 400 1300 mg least four divided dos , prior initial screen assessment 6 . Able complete Hauser home diary tell difference `` On Off '' time 7 . Able adhere visit schedule , protocol requirement available complete study 8 . At least 2.5 hour `` Off time '' per day waking hour Screening 2Day Hauser Home Diary , ( morning akinesia incorporate total `` Off time '' assessment ) Main 1 . Participation another drug clinical trial within 28 day prior initial screen assessment ( calculate previous study 's last dosing date ) 2 . Atypical Parkinsonism ( subject Parkinsonian feature cause disorder multiple system atrophy , progressive supranuclear palsy , dementia Lewy body multiple brain infarct ) 3 . Clinically significant cardiac , pulmonary , hepatic renal disease condition major complication/illness contraindicate his/her participation 4 . Treatment COMT inhibitor last 28 day prior initial screen assessment 5 . Treatment nonselective monoamine oxidase ( MAO ) inhibitor last 28 day prior initial screen assessment plan take study participation 6 . Previous plan neurosurgical treatment Parkinson 's Disease ( e.g. , procedure include ablation deep brain stimulation ) course study 7 . Significant cognitive impairment define MiniMental State Examination ( MMSE ) score &lt; 26 . 8 . Clinically significant psychiatric illness , include major depression ( Hamilton Depression Rating Scale17 ≥14 ) . Subjects lifetime history suicidal attempt ( include active attempt , interrupt attempt aborted attempt ) 9 . Current previous treatment 1 month within past 2 year neuroleptic drug ( antipsychotic ) drug antidopaminergic property ( e.g . metoclopramide ) . 10 . Currently experience know history psychosis delusion within 2 year prior Screening . 11 . Known history substance abuse within past 2 year 12 . Moderate great level alcohol consumption 13 . Unable swallow large pill ( e.g. , large vitamin pill ) 14 . History Melanoma suspicious skin lesion could Melanoma 15 . Narrowangle Glaucoma 16 . History small bowel gastric surgery ( Including PEGJ placement Duopa/Duodopa ) bowel obstruction , diagnosis small bowel narrowing , diagnosis Crohn 's disease , frequent nausea emesis , regardless etiology contraindicate his/her participation study . ( Previous appendectomy hernioplasty exclusionary . 17 . Active peptic ulcer disease history peptic ulcer upper GI bleed 18 . Regular use opioids ( Intermittent opioid use exclusionary ) 19 . Symptomatic gastroparesis frequent vomit ( least week ) 20 . Concomitant use NSAIDs oral steroid within past 28 day 21 . Allergy study drug excipients , Yellow Dye # 5 ( tartrazine ) 22 . Women pregnant nursing . Women childbearing potential willing use medically acceptable method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Fluctuating Parkinson 's Disease</keyword>
	<keyword>Advanced Parkinson 's Disease</keyword>
	<keyword>Carbidopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Accordion</keyword>
	<keyword>Accordance</keyword>
</DOC>